OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
Haohao Li, Alison Zhao, Meng-Hua Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Haohao Li, Alison Zhao, Meng-Hua Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 19
Showing 19 citing articles:
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Xianjing Chu, Wentao Tian, Ziqi Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 87
Xianjing Chu, Wentao Tian, Ziqi Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 87
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1397-1397
Open Access | Times Cited: 25
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1397-1397
Open Access | Times Cited: 25
GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma
Ruixin Sun, Yifan Liu, Yansha Sun, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 9, pp. 1937-1950
Closed Access | Times Cited: 9
Ruixin Sun, Yifan Liu, Yansha Sun, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 9, pp. 1937-1950
Closed Access | Times Cited: 9
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access
Role of liposomes in chemoimmunotherapy of Breast cancer
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Fatemeh Attarian, Ghazaleh Hatamian, Shamim Nosrati, et al.
Journal of drug targeting (2025), pp. 1-43
Closed Access
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Saud Almawash
Cancers (2025) Vol. 17, Iss. 5, pp. 880-880
Open Access
Saud Almawash
Cancers (2025) Vol. 17, Iss. 5, pp. 880-880
Open Access
Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations
Hsuan-Chia Chang, Chung‐Ying Tsai, Cheng-Lung Hsu, et al.
Nature Metabolism (2025)
Open Access
Hsuan-Chia Chang, Chung‐Ying Tsai, Cheng-Lung Hsu, et al.
Nature Metabolism (2025)
Open Access
Cancer Bioenergetics and Tumor Microenvironments—Enhancing Chemotherapeutics and Targeting Resistant Niches through Nanosystems
Aisha Farhana, Abdullah Alsrhani, Yusuf S. Khan, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3836-3836
Open Access | Times Cited: 12
Aisha Farhana, Abdullah Alsrhani, Yusuf S. Khan, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3836-3836
Open Access | Times Cited: 12
Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions
Dhana Sekhar Reddy Bandi, Sujith Sarvesh, Batoul Farran, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 71-72, pp. 26-39
Closed Access | Times Cited: 11
Dhana Sekhar Reddy Bandi, Sujith Sarvesh, Batoul Farran, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 71-72, pp. 26-39
Closed Access | Times Cited: 11
Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management
Salem Baldi, Mohammed Alnaggar, Maged AL-Mogahed, et al.
The EPMA Journal (2025)
Closed Access
Salem Baldi, Mohammed Alnaggar, Maged AL-Mogahed, et al.
The EPMA Journal (2025)
Closed Access
Molecular insight into T cell exhaustion in hepatocellular carcinoma
Yonghua Zhu, Huabing Tan, Jincheng Wang, et al.
Pharmacological Research (2024) Vol. 203, pp. 107161-107161
Open Access | Times Cited: 3
Yonghua Zhu, Huabing Tan, Jincheng Wang, et al.
Pharmacological Research (2024) Vol. 203, pp. 107161-107161
Open Access | Times Cited: 3
Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
Masanori Oshi, Arya Mariam Roy, Yan Li, et al.
PubMed (2023) Vol. 13, Iss. 7, pp. 3041-3054
Closed Access | Times Cited: 8
Masanori Oshi, Arya Mariam Roy, Yan Li, et al.
PubMed (2023) Vol. 13, Iss. 7, pp. 3041-3054
Closed Access | Times Cited: 8
Global trends and research hotspots of PCSK9 and cardiovascular disease: a bibliometric and visual analysis
Masong Tang, Sen Yang, Junying Zou, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Masong Tang, Sen Yang, Junying Zou, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy
Zhenzhen Li, Bingqian Han, Menghui Qi, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189172-189172
Closed Access | Times Cited: 1
Zhenzhen Li, Bingqian Han, Menghui Qi, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189172-189172
Closed Access | Times Cited: 1
Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies
Xintong Peng, Jingfan Zheng, Tianzi Liu, et al.
Current Cancer Drug Targets (2023) Vol. 24, Iss. 3, pp. 288-307
Closed Access | Times Cited: 3
Xintong Peng, Jingfan Zheng, Tianzi Liu, et al.
Current Cancer Drug Targets (2023) Vol. 24, Iss. 3, pp. 288-307
Closed Access | Times Cited: 3
Cancer nanoimmunotherapy in the present scenario
Alejandra Ancira-Cortez, Brenda Gibbens-Bandala, Pedro Cruz-Nova, et al.
Elsevier eBooks (2024), pp. 653-681
Closed Access
Alejandra Ancira-Cortez, Brenda Gibbens-Bandala, Pedro Cruz-Nova, et al.
Elsevier eBooks (2024), pp. 653-681
Closed Access
Immunometabolic Targets in CD8+ T Cells within the Tumor Microenvironment of Hepatocellular Carcinoma
Yu‐Hsuan Lin, Rexiati Ruze, Ruiqing Zhang, et al.
Liver Cancer (2024), pp. 1-30
Open Access
Yu‐Hsuan Lin, Rexiati Ruze, Ruiqing Zhang, et al.
Liver Cancer (2024), pp. 1-30
Open Access
Immunotherapy in cancer: Where we are and what the future brings?
Krsek Antea, Krpina Kristina, Samarzija Miroslav, et al.
Trends in Immunotherapy (2023) Vol. 7, Iss. 2, pp. 2186-2186
Open Access | Times Cited: 1
Krsek Antea, Krpina Kristina, Samarzija Miroslav, et al.
Trends in Immunotherapy (2023) Vol. 7, Iss. 2, pp. 2186-2186
Open Access | Times Cited: 1
Modulating Immune Response in Viral Infection for Quantitative Forecasts of Drug Efficacy
Bárbara Costa, Nuno Vale
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 167-167
Open Access
Bárbara Costa, Nuno Vale
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 167-167
Open Access
